Compare Abbott Laboratories (ABT) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Abbott Laboratories trades at $95.51 (market cap $166.94B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $251.92 (market cap $47.86B). The key difference: Abbott Laboratories is far larger — about 3.5× TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock's market cap, and Abbott Laboratories pays a 2.63% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals.
| ABT | TTWO | |
|---|---|---|
Market Cap | $166.94B | $47.86B |
Sector | Health | Media |
52-Week High | $136.62 | $262.29 |
52-Week Low | $82.57 | $189.69 |
Enterprise Value | $193.69B | $48.83B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Take-Two Interactive (TTWO) trades at $257.79, up 1.12% with strong bullish momentum driven by Grand Theft Auto VI pre-orders and recent earnings beats. The stock shows technical strength with bullish moving averages, though RSI indicates overbought conditions. Despite negative net income margins, revenue growth to $5.63B in 2025 and analyst consensus of $302.50 price target reflect optimism around the GTA VI launch in November 2026.
Outlook remains positive with GTA VI as a major catalyst, but risks include high debt levels and profitability challenges. Institutional sentiment is strongly bullish with 79% buy ratings, yet investors should monitor execution risks and competitive pressures in the gaming sector. The stock's valuation metrics like P/S of 7.14 suggest growth expectations are priced in.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
